$AVTX
Avalo Therapeutics, Inc. Stock $avtx

$avtx Overview Financials Valuation SEC Filings Company Website

2018 Q1 Form 10-K Financial Statement

#000162828018003890 Filed on April 02, 2018

Income Statement

Concept	2018 Q1	2017 Q4	2017 Q3
Revenue	$4.483M	$1.911M	$25.04M
YoY Change	1066.76%	950.0%	7687.82%
Cost Of Revenue	$863.6K	$636.0K	$0.00
YoY Change
Gross Profit	$3.619M	$1.275M	$25.04M
YoY Change	841.98%
Gross Profit Margin	80.73%	66.72%	100.0%
Selling, General & Admin	$4.444M	$3.994M	$2.152M
YoY Change	234.05%	266.42%	26.58%
% of Gross Profit	122.78%	313.25%	8.59%
Research & Development	$1.650M	$1.961M	$965.0K
YoY Change	73.1%	153.69%	-78.94%
% of Gross Profit	45.58%	153.8%	3.85%
Depreciation & Amortization	$1.023M	$410.0K	$10.00K
YoY Change	17447.86%	4000.0%	0.0%
% of Gross Profit	28.27%	32.16%	0.04%
Operating Expenses	$8.237M	$5.955M	$3.116M
YoY Change	260.76%	670.38%	-31.99%
Operating Profit	-$3.755M	-$4.680M	$21.92M
YoY Change	97.7%		-467.6%
Interest Expense	-$100.4K	$31.00K	$29.39K
YoY Change	73.86%	-137.35%	-128.26%
% of Operating Profit			0.13%
Other Income/Expense, Net	-$105.0K		$29.45K
YoY Change	70.7%		-114.34%
Pretax Income	-$3.860M	-$4.360M	$21.95M
YoY Change	96.94%	165.85%	-455.84%
Income Tax	$23.31K	-$3.460M	$3.230M
% Of Pretax Income			14.71%
Net Earnings	-$3.883M	-$3.091M	$18.72M
YoY Change	98.04%	88.59%	-403.46%
Net Earnings / Revenue	-86.62%	-161.75%	74.77%
Basic Earnings Per Share		-$0.11	$0.52
Diluted Earnings Per Share	-$1.46	-$0.11	$0.52
COMMON SHARES
Basic Shares Outstanding	31.38M shares	26.05M shares	21.38M shares
Diluted Shares Outstanding			21.41M shares

Balance Sheet

Concept	2018 Q1	2017 Q4	2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.520M	$2.470M	$23.96M
YoY Change	-16.0%	-51.85%	171.66%
Cash & Equivalents	$2.524M	$2.472M	$23.96M
Short-Term Investments
Other Short-Term Assets	$780.0K	$700.0K	$370.0K
YoY Change	188.89%	75.0%	23.33%
Inventory	$3.440M	$382.2K
Prepaid Expenses
Receivables	$2.830M	$2.940M
Other Receivables	$3.810M	$4.170M
Total Short-Term Assets	$13.39M	$10.67M	$28.11M
YoY Change	287.22%	88.5%	196.17%
LONG-TERM ASSETS
Property, Plant & Equipment	$58.21K	$44.61K	$34.18K
YoY Change	48.43%	3.17%	-14.54%
Goodwill	$18.68M	$12.29M
YoY Change
Intangibles	$33.10M	$17.66M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$130.0K	$130.0K	$60.00K
YoY Change	116.67%	116.67%	20.0%
Total Long-Term Assets	$51.97M	$32.13M	$97.03K
YoY Change	50825.18%	30193.6%	7.81%
TOTAL ASSETS
Total Short-Term Assets	$13.39M	$10.67M	$28.11M
Total Long-Term Assets	$51.97M	$32.13M	$97.03K
Total Assets	$65.36M	$42.81M	$28.20M
YoY Change	1735.58%	642.03%	194.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.166M	$1.299M	$312.5K
YoY Change	431.31%	28.59%	-61.42%
Accrued Expenses	$6.980M	$7.530M	$1.290M
YoY Change	990.63%	701.06%	-61.61%
Deferred Revenue		$0.00
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$787.5K	$0.00	$0.00
YoY Change	-47.23%	-100.0%	-100.0%
Total Short-Term Liabilities	$14.79M	$11.09M	$4.833M
YoY Change	440.41%	157.18%	-35.56%
LONG-TERM LIABILITIES
Long-Term Debt	$14.59M	$0.00	$0.00
YoY Change	877.67%
Other Long-Term Liabilities	$304.2K	$24.27K	$1.250M
YoY Change	-75.66%		-16.67%
Total Long-Term Liabilities	$14.89M	$24.27K	$0.00
YoY Change	898.05%		-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.79M	$11.09M	$4.833M
Total Long-Term Liabilities	$14.89M	$24.27K	$0.00
Total Liabilities	$40.78M	$14.95M	$6.083M
YoY Change	922.89%	168.75%	-32.41%
SHAREHOLDERS EQUITY
Retained Earnings	-$62.00M	-$58.17M	-$55.10M
YoY Change	-13.88%	-16.95%
Common Stock	$31.41K	$31.27K	$26.06K
YoY Change	188.15%	231.44%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$24.58M	$27.86M	$22.12M
YoY Change
Total Liabilities & Shareholders Equity	$65.36M	$42.81M	$28.20M
YoY Change	1735.58%	642.03%	194.4%

Cashflow Statement

Concept	2018 Q1	2017 Q4	2017 Q3
OPERATING ACTIVITIES
Net Income	-$3.883M	-$3.091M	$18.72M
YoY Change	98.04%	88.59%	-403.46%
Depreciation, Depletion And Amortization	$1.023M	$410.0K	$10.00K
YoY Change	17447.86%	4000.0%	0.0%
Cash From Operating Activities	-$280.4K	-$2.550M	$19.13M
YoY Change	-87.46%	-31.27%	-657.73%
INVESTING ACTIVITIES
Capital Expenditures	$19.22K	$10.00K	$10.00K
YoY Change	967.41%		0.0%
Acquisitions	$1.00
YoY Change
Other Investing Activities	$0.00	-$18.89M	$0.00
YoY Change
Cash From Investing Activities	-$19.23K	-$18.90M	-$10.00K
YoY Change	967.46%		0.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00
YoY Change	-100.0%
Debt Paid & Issued, Net	$0.00
YoY Change	-100.0%
Cash From Financing Activities	$363.4K	10.00K	-600.0K
YoY Change	200.42%	-66.67%	-257.89%
NET CHANGE
Cash From Operating Activities	-$280.4K	-2.550M	19.13M
Cash From Investing Activities	-$19.23K	-18.90M	-10.00K
Cash From Financing Activities	$363.4K	10.00K	-600.0K
Net Change In Cash	$63.74K	-21.44M	18.52M
YoY Change	-103.01%	482.61%	-705.23%
FREE CASH FLOW
Cash From Operating Activities	-$280.4K	-$2.550M	$19.13M
Capital Expenditures	$19.22K	$10.00K	$10.00K
Free Cash Flow	-$299.6K	-$2.560M	$19.12M
YoY Change	-86.61%	-31.0%	-655.81%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017	cerc	Accounts Receivable Payment Terms AccountsReceivablePaymentTerms	P30D
CY2016Q4	cerc	Accrued General And Administrative Expenses AccruedGeneralAndAdministrativeExpenses	160116	USD
CY2017Q4	cerc	Accrued General And Administrative Expenses AccruedGeneralAndAdministrativeExpenses	1001454	USD
CY2016Q4	cerc	Accrued Liabilities And Other Current Liabilities AccruedLiabilitiesAndOtherCurrentLiabilities	942435	USD
CY2017Q4	cerc	Accrued Liabilities And Other Current Liabilities AccruedLiabilitiesAndOtherCurrentLiabilities	7848309	USD
CY2016Q4	cerc	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	315937	USD
CY2017Q4	cerc	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	299480	USD
CY2016Q4	cerc	Accrued Sales Returns And Allowances AccruedSalesReturnsAndAllowances	0	USD
CY2017Q4	cerc	Accrued Sales Returns And Allowances AccruedSalesReturnsAndAllowances	4146217	USD
CY2015	cerc	Amortization Of Inventory Fair Value Adjustment AmortizationOfInventoryFairValueAdjustment	0	USD
CY2016	cerc	Amortization Of Inventory Fair Value Adjustment AmortizationOfInventoryFairValueAdjustment	0	USD
CY2017	cerc	Amortization Of Inventory Fair Value Adjustment AmortizationOfInventoryFairValueAdjustment	137900	USD
CY2017Q4	cerc	Capital Stock Shares Authorized CapitalStockSharesAuthorized	205000000	shares
CY2017	cerc	Concentration Risk Number Of Product Lines ConcentrationRiskNumberOfProductLines	5	product_line
CY2017	cerc	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	0.0002
CY2015	cerc	Effective Income Tax Rate Reconciliation Warrants EffectiveIncomeTaxRateReconciliationWarrants	0.0426
CY2016	cerc	Effective Income Tax Rate Reconciliation Warrants EffectiveIncomeTaxRateReconciliationWarrants	0.0015
CY2017	cerc	Effective Income Tax Rate Reconciliation Warrants EffectiveIncomeTaxRateReconciliationWarrants	0.0007
CY2016Q4	cerc	Deferred Tax Assets Net Before Valuation Allowance DeferredTaxAssetsNetBeforeValuationAllowance	30874531	USD
CY2017Q4	cerc	Deferred Tax Assets Net Before Valuation Allowance DeferredTaxAssetsNetBeforeValuationAllowance	4016846	USD
CY2016Q4	cerc	Deferred Tax Assets Tax Difference In Tangible And Intangible Assets DeferredTaxAssetsTaxDifferenceInTangibleAndIntangibleAssets	6174163	USD
CY2017Q4	cerc	Deferred Tax Assets Tax Difference In Tangible And Intangible Assets DeferredTaxAssetsTaxDifferenceInTangibleAndIntangibleAssets	2554924	USD
CY2016Q4	cerc	Deferred Tax Liabilities Tax Deferred Expense Basis Difference In Intangible Assets DeferredTaxLiabilitiesTaxDeferredExpenseBasisDifferenceInIntangibleAssets	0	USD
CY2017Q4	cerc	Deferred Tax Liabilities Tax Deferred Expense Basis Difference In Intangible Assets DeferredTaxLiabilitiesTaxDeferredExpenseBasisDifferenceInIntangibleAssets	535652	USD
CY2016Q4	cerc	Deferred Tax Liabilities Tax Deferred Expense Installment Sale DeferredTaxLiabilitiesTaxDeferredExpenseInstallmentSale	0	USD
CY2017Q4	cerc	Deferred Tax Liabilities Tax Deferred Expense Installment Sale DeferredTaxLiabilitiesTaxDeferredExpenseInstallmentSale	358844	USD
CY2015	cerc	Effective Income Tax Rate Reconciliation Acquisition Costs Percent EffectiveIncomeTaxRateReconciliationAcquisitionCostsPercent	0.0000
CY2016	cerc	Effective Income Tax Rate Reconciliation Acquisition Costs Percent EffectiveIncomeTaxRateReconciliationAcquisitionCostsPercent	0.0000
CY2017	cerc	Effective Income Tax Rate Reconciliation Acquisition Costs Percent EffectiveIncomeTaxRateReconciliationAcquisitionCostsPercent	0.0008
CY2015	cerc	Effective Income Tax Rate Reconciliation Built In Loss Percent EffectiveIncomeTaxRateReconciliationBuiltInLossPercent	0.0000
CY2016	cerc	Effective Income Tax Rate Reconciliation Built In Loss Percent EffectiveIncomeTaxRateReconciliationBuiltInLossPercent	0.0000
CY2017	cerc	Effective Income Tax Rate Reconciliation Built In Loss Percent EffectiveIncomeTaxRateReconciliationBuiltInLossPercent	0.0152
CY2015	cerc	Effective Income Tax Rate Reconciliation Net Operating Loss Adjustment Per Section382 Percent EffectiveIncomeTaxRateReconciliationNetOperatingLossAdjustmentPerSection382Percent	0.0000
CY2016	cerc	Effective Income Tax Rate Reconciliation Net Operating Loss Adjustment Per Section382 Percent EffectiveIncomeTaxRateReconciliationNetOperatingLossAdjustmentPerSection382Percent	0.0000
CY2017	cerc	Effective Income Tax Rate Reconciliation Net Operating Loss Adjustment Per Section382 Percent EffectiveIncomeTaxRateReconciliationNetOperatingLossAdjustmentPerSection382Percent	1.2682
CY2015	cerc	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.0002
CY2016	cerc	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.0002
CY2017Q4	cerc	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Recognized In Next Twelve Months EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostRecognizedInNextTwelveMonths	732441	USD
CY2017Q4	cerc	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Recognized Year Four EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostRecognizedYearFour	68623	USD
CY2017Q4	cerc	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Recognized Year Three EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostRecognizedYearThree	188351	USD
CY2017Q4	cerc	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Recognized Year Two EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostRecognizedYearTwo	352657	USD
CY2017Q3	cerc	Escrow Period EscrowPeriod	P12M
CY2017Q3	cerc	Escrow Period EscrowPeriod	P12M
CY2015	cerc	Fair Value Adjustment Of Warrants And Investor Rights Obligation FairValueAdjustmentOfWarrantsAndInvestorRightsObligation	-1313049	USD
CY2016Q1	cerc	Fair Value Adjustment Of Warrants And Investor Rights Obligation FairValueAdjustmentOfWarrantsAndInvestorRightsObligation	47000	USD
CY2016Q2	cerc	Fair Value Adjustment Of Warrants And Investor Rights Obligation FairValueAdjustmentOfWarrantsAndInvestorRightsObligation	-91000	USD
CY2016Q3	cerc	Fair Value Adjustment Of Warrants And Investor Rights Obligation FairValueAdjustmentOfWarrantsAndInvestorRightsObligation	101000	USD
CY2016Q4	cerc	Fair Value Adjustment Of Warrants And Investor Rights Obligation FairValueAdjustmentOfWarrantsAndInvestorRightsObligation	-130000	USD
CY2016	cerc	Fair Value Adjustment Of Warrants And Investor Rights Obligation FairValueAdjustmentOfWarrantsAndInvestorRightsObligation	-72625	USD
CY2017Q1	cerc	Fair Value Adjustment Of Warrants And Investor Rights Obligation FairValueAdjustmentOfWarrantsAndInvestorRightsObligation	4000	USD
CY2017Q2	cerc	Fair Value Adjustment Of Warrants And Investor Rights Obligation FairValueAdjustmentOfWarrantsAndInvestorRightsObligation	-2000	USD
CY2017Q3	cerc	Fair Value Adjustment Of Warrants And Investor Rights Obligation FairValueAdjustmentOfWarrantsAndInvestorRightsObligation	0	USD
CY2017Q4	cerc	Fair Value Adjustment Of Warrants And Investor Rights Obligation FairValueAdjustmentOfWarrantsAndInvestorRightsObligation	28000	USD
CY2017	cerc	Fair Value Adjustment Of Warrants And Investor Rights Obligation FairValueAdjustmentOfWarrantsAndInvestorRightsObligation	29624	USD
CY2016	cerc	Fair Value Measurements Changes In Valuation Techniques Number FairValueMeasurementsChangesInValuationTechniquesNumber	0	class_of_stock
CY2017	cerc	Fair Value Measurements Changes In Valuation Techniques Number FairValueMeasurementsChangesInValuationTechniquesNumber	0	class_of_stock
CY2016Q4	cerc	License Obligation Noncurrent LicenseObligationNoncurrent	1250000	USD
CY2017Q4	cerc	License Obligation Noncurrent LicenseObligationNoncurrent	1250000	USD
CY2015	cerc	Net Income Loss Available To Common Stockholders Diluted Before Reallocation NetIncomeLossAvailableToCommonStockholdersDilutedBeforeReallocation	-10490103	USD
CY2016	cerc	Net Income Loss Available To Common Stockholders Diluted Before Reallocation NetIncomeLossAvailableToCommonStockholdersDilutedBeforeReallocation	-16471603	USD
CY2017	cerc	Net Income Loss Available To Common Stockholders Diluted Before Reallocation NetIncomeLossAvailableToCommonStockholdersDilutedBeforeReallocation	7772084	USD
CY2015	cerc	Net Income Loss Available To Common Stockholders Diluted Reallocated NetIncomeLossAvailableToCommonStockholdersDilutedReallocated	0	USD
CY2016	cerc	Net Income Loss Available To Common Stockholders Diluted Reallocated NetIncomeLossAvailableToCommonStockholdersDilutedReallocated	0	USD
CY2017	cerc	Net Income Loss Available To Common Stockholders Diluted Reallocated NetIncomeLossAvailableToCommonStockholdersDilutedReallocated	49642	USD
CY2017Q4	cerc	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue	669816	USD
CY2016	cerc	Share Based Compensation Arrangement By Share Based Payment Award Share Reserve Increase As Percent ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent	0.04
CY2015	cerc	Stock Issued During Period Value Acquisitions Contingent Shares StockIssuedDuringPeriodValueAcquisitionsContingentShares	0	USD
CY2016	cerc	Stock Issued During Period Value Acquisitions Contingent Shares StockIssuedDuringPeriodValueAcquisitionsContingentShares	0	USD
CY2015	cerc	Net Income Loss Before Taxes NetIncomeLossBeforeTaxes	-10490103	USD
CY2016	cerc	Net Income Loss Before Taxes NetIncomeLossBeforeTaxes	-16471603	USD
CY2017	cerc	Net Income Loss Before Taxes NetIncomeLossBeforeTaxes	13836342	USD
CY2015Q4	cerc	Number Of Class Of Stock Authorized NumberOfClassOfStockAuthorized	2	class_of_stock
CY2016	cerc	Number Of Material Adjustments To Prior Period Estimates Of Accrued Expenses NumberOfMaterialAdjustmentsToPriorPeriodEstimatesOfAccruedExpenses	0	class_of_stock
CY2017	cerc	Number Of Material Adjustments To Prior Period Estimates Of Accrued Expenses NumberOfMaterialAdjustmentsToPriorPeriodEstimatesOfAccruedExpenses	0	class_of_stock
CY2017	cerc	Number Of Products In Development NumberOfProductsInDevelopment	3	product
CY2015	cerc	Payment Of Fractional Shares Upon Conversion Of Preferred Stock To Common Stock PaymentOfFractionalSharesUponConversionOfPreferredStockToCommonStock	1373	USD
CY2016	cerc	Payment Of Fractional Shares Upon Conversion Of Preferred Stock To Common Stock PaymentOfFractionalSharesUponConversionOfPreferredStockToCommonStock	0	USD
CY2017	cerc	Payment Of Fractional Shares Upon Conversion Of Preferred Stock To Common Stock PaymentOfFractionalSharesUponConversionOfPreferredStockToCommonStock	-4	USD
CY2015	cerc	Payments Of Stock Issuance Costs Excluding Amounts Paid To Underwriters PaymentsOfStockIssuanceCostsExcludingAmountsPaidToUnderwriters	2269171	USD
CY2016	cerc	Payments Of Stock Issuance Costs Excluding Amounts Paid To Underwriters PaymentsOfStockIssuanceCostsExcludingAmountsPaidToUnderwriters	114945	USD
CY2017	cerc	Payments Of Stock Issuance Costs Excluding Amounts Paid To Underwriters PaymentsOfStockIssuanceCostsExcludingAmountsPaidToUnderwriters	279247	USD
CY2013	cerc	Period Of Abatement PeriodOfAbatement	P3M
CY2017Q3	cerc	Potential Future Regulatory Milestone PotentialFutureRegulatoryMilestone	20000000	USD
CY2017Q4	cerc	Reserve Escrow Receivable ReserveEscrowReceivable	0	USD
CY2017	cerc	Sales Discounts Percent SalesDiscountsPercent	0.02
CY2013Q3	cerc	Security Deposit Required At End Of Lease Term SecurityDepositRequiredAtEndOfLeaseTerm	13000	USD
CY2016Q4	cerc	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue	2155234	USD
CY2017	cerc	Stock Issued During Period Value Acquisitions Contingent Shares StockIssuedDuringPeriodValueAcquisitionsContingentShares	2655464	USD
CY2017	cerc	Stock Issued During Period Value New Issues Private Placement StockIssuedDuringPeriodValueNewIssuesPrivatePlacement	4561654	USD
CY2017Q4	cerc	Stockbased Compensation Number Of Board Members That Resigned During Period StockbasedCompensationNumberOfBoardMembersThatResignedDuringPeriod	2	board_member
CY2017	cerc	Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Deferred Tax Asset Provisional Income Tax Expense TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalIncomeTaxExpense	2200000	USD
CY2016Q3	cerc	Threshold Price Per Common Stock On Any Trading Day To Present Notice For Purchase Of Common Stock ThresholdPricePerCommonStockOnAnyTradingDayToPresentNoticeForPurchaseOfCommonStock	0.50
CY2017	dei	Amendment Flag AmendmentFlag	false
CY2017	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2017	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017	dei	Document Period End Date DocumentPeriodEndDate	2017-12-31
CY2017	dei	Document Type DocumentType	10-K
CY2017	dei	Entity Central Index Key EntityCentralIndexKey	0001534120
CY2018Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	31379778	shares
CY2017	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2017	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2017Q2	dei	Entity Public Float EntityPublicFloat	5882756	USD
CY2017	dei	Entity Registrant Name EntityRegistrantName	Cerecor Inc.
CY2017	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2017	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1010209	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1298980	USD
CY2016Q4	us-gaap	Accounts Receivable Billed For Long Term Contracts Or Programs AccountsReceivableBilledForLongTermContractsOrPrograms	0	USD
CY2017Q4	us-gaap	Accounts Receivable Billed For Long Term Contracts Or Programs AccountsReceivableBilledForLongTermContractsOrPrograms	427241	USD
CY2016Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	132472	USD
CY2017Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	3252212	USD
CY2016Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	0	USD
CY2017Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	2259148	USD
CY2016Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	947987	USD
CY2017Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	7848309	USD
CY2016Q4	us-gaap	Accrued Royalties Current And Noncurrent AccruedRoyaltiesCurrentAndNoncurrent	0	USD
CY2017Q4	us-gaap	Accrued Royalties Current And Noncurrent AccruedRoyaltiesCurrentAndNoncurrent	743010	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	87691	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	109647	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	70232651	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	83338136	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	394748	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1694891	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1157252	USD
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	394748	USD
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1694891	USD
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1157252	USD
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2016	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	USD
CY2017	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	403520	USD
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
CY2016Q4	us-gaap	Assets Assets	5768865	USD
CY2017Q4	us-gaap	Assets Assets	43124094	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	5662794	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	10991367	USD
CY2016Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	0	USD
CY2017Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	2576633	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11742349	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21161967	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5127958	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2500000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2472187	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	9419618	USD
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-16034009	USD
CY2017	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2655771	USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9434141	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31266989	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9434141	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31266989	shares
CY2015	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2016	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	9434	USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	31268	USD
CY2016Q4	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	0	USD
CY2017Q4	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	2655464	USD
CY2015	us-gaap	Contracts Revenue ContractsRevenue	0	USD
CY2016	us-gaap	Contracts Revenue ContractsRevenue	0	USD
CY2017Q1	us-gaap	Contracts Revenue ContractsRevenue	0	USD
CY2017Q2	us-gaap	Contracts Revenue ContractsRevenue	0	USD
CY2017Q3	us-gaap	Contracts Revenue ContractsRevenue	0	USD
CY2017Q4	us-gaap	Contracts Revenue ContractsRevenue	278000	USD
CY2017	us-gaap	Contracts Revenue ContractsRevenue	278165	USD
CY2015	us-gaap	Cost Of Goods Sold CostOfGoodsSold	0	USD
CY2016	us-gaap	Cost Of Goods Sold CostOfGoodsSold	0	USD
CY2017Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	0	USD
CY2017Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	0	USD
CY2017Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	0	USD
CY2017Q4	us-gaap	Cost Of Goods Sold CostOfGoodsSold	636000	USD
CY2017	us-gaap	Cost Of Goods Sold CostOfGoodsSold	635648	USD
CY2015	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	0	USD
CY2016	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	0	USD
CY2017	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	489863	USD
CY2016	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2017	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	2309285	USD
CY2015	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2017	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2799148	USD
CY2016Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	2374031	USD
CY2017Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	0	USD
CY2016Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	20364	USD
CY2017Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	0	USD
CY2016Q4	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	2353667	USD
CY2017Q4	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	0	USD
CY2015	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2016	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2017	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-789274	USD
CY2015	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2016	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-832629	USD
CY2016Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	0	USD
CY2017Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	894496	USD
CY2016Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	0	USD
CY2017Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	7144	USD
CY2015	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2016	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2017	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-43355	USD
CY2015	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	23508	USD
CY2016	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	26856	USD
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.1421
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2017Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	7144	USD
CY2016Q4	us-gaap	Deposits Deposits	50000	USD
CY2016	us-gaap	Depreciation Depreciation	26856	USD
CY2017	us-gaap	Depreciation Depreciation	21956	USD
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	30874531	USD
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	4911342	USD
CY2016Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	20587955	USD
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	716819	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1840505	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	0	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	90936	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	271437	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2169070	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1291230	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	11902	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	4051	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	0	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	72881	USD
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	30874531	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4023990	USD
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	425476	USD
CY2015	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.71
CY2016	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.87
CY2017Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2017Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
CY2017Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.52
CY2017Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2017	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.42
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.59
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.41
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.70
CY2016Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.18
CY2015	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.71
CY2016	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.87
CY2017Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
CY2017Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2017Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.52
CY2017Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
CY2017	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.42
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2017Q4	us-gaap	Goodwill Goodwill	14292282	USD
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.4608
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.3975
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-1.9103
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.0000
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.0000
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.1582
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.0003
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.0000
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.0004
CY2015	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0512
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0344
CY2017	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.2791
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0269
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0218
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.0104
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	272601	USD
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1401514	USD
CY2017Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	1342072	USD
CY2016Q4	us-gaap	Escrow Deposit EscrowDeposit	0	USD
CY2017Q4	us-gaap	Escrow Deposit EscrowDeposit	3752390	USD
CY2017Q3	us-gaap	Escrow Deposit EscrowDeposit	3750000	USD
CY2017Q3	us-gaap	Escrow Deposit EscrowDeposit	3750000	USD
CY2016Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2017Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2016Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0	USD
CY2017Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	403520	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	6889457	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	3228167	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	697667	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1728867	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2038030	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	3082292	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	18068000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	17664480	USD
CY2015	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4422764	USD
CY2016Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2649000	USD
CY2016Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1636000	USD
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1703000	USD
CY2016Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1095000	USD
CY2016	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7083155	USD
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1330000	USD
CY2017Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1439000	USD
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2152000	USD
CY2017	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	14292282	USD
CY2017Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3021000	USD
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7941584	USD
CY2016Q4	us-gaap	Goodwill Goodwill	0	USD
CY2017Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	0	USD
CY2017	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1966519	USD
CY2015	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2016	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2017	us-gaap	Income Taxes Paid IncomeTaxesPaid	540000	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-268709	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	332100	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	96065	USD
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	USD
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	132472	USD
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	247195	USD
CY2015	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	0	USD
CY2016	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	0	USD
CY2017	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	2259148	USD
CY2015	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	0	USD
CY2016	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	0	USD
CY2017	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	3752390	USD
CY2015	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
CY2016	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	202622	USD
CY2015	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	1121054	USD
CY2016	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-119495	USD
CY2017	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	2044548	USD
CY2015	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	0	USD
CY2016	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	0	USD
CY2017	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	427241	USD
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	41243	USD
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-22047	USD
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	177691	USD
CY2015	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	-116666	USD
CY2016	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	15107	USD
CY2017	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	59373	USD
CY2015	us-gaap	Incremental Common Shares Attributable To Equity Unit Purchase Agreements IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements	0	shares
CY2016	us-gaap	Incremental Common Shares Attributable To Equity Unit Purchase Agreements IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements	0	shares
CY2017	us-gaap	Incremental Common Shares Attributable To Equity Unit Purchase Agreements IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements	283284	shares
CY2015	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2016	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2017	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	61510	shares
CY2016Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	0	USD
CY2017Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	18068000	USD
CY2016Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	0	USD
CY2017Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	17664480	USD
CY2015	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-793205	USD
CY2016Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-151000	USD
CY2015	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
CY2017Q4	us-gaap	Liabilities Liabilities	15264486	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5768865	USD
CY2016	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
CY2016	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
CY2016Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-127000	USD
CY2017	us-gaap	Inventory Write Down InventoryWriteDown	178346	USD
CY2016Q4	us-gaap	Liabilities Liabilities	5561863	USD
CY2016Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-104000	USD
CY2017Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	178346	USD
CY2016Q4	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-83000	USD
CY2016	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-464181	USD
CY2017Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-58000	USD
CY2017Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-26000	USD
CY2017Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	29000	USD
CY2017Q4	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	31000	USD
CY2017	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-24016	USD
CY2015	us-gaap	Interest Paid InterestPaid	568299	USD
CY2016	us-gaap	Interest Paid InterestPaid	348888	USD
CY2017	us-gaap	Interest Paid InterestPaid	72526	USD
CY2016Q4	us-gaap	Interest Payable Current InterestPayableCurrent	193781	USD
CY2017Q4	us-gaap	Interest Payable Current InterestPayableCurrent	0	USD
CY2017Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	382153	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	0	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	382153	USD
CY2016Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	0	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	43124094	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4311863	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11406437	USD
CY2017Q3	us-gaap	Licenses Revenue LicensesRevenue	25000000	USD
CY2017Q3	us-gaap	Licenses Revenue LicensesRevenue	25000000	USD
CY2015	us-gaap	Licenses Revenue LicensesRevenue	0	USD
CY2016	us-gaap	Licenses Revenue LicensesRevenue	0	USD
CY2017Q1	us-gaap	Licenses Revenue LicensesRevenue	0	USD
CY2017Q2	us-gaap	Licenses Revenue LicensesRevenue	0	USD
CY2017Q3	us-gaap	Licenses Revenue LicensesRevenue	25000000	USD
CY2017Q4	us-gaap	Licenses Revenue LicensesRevenue	0	USD
CY2017	us-gaap	Licenses Revenue LicensesRevenue	25000000	USD
CY2016Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2353667	USD
CY2017Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2016Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	USD
CY2017Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	19602982	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1425988	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3737081	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-19984	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-34883	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	18721000	USD
CY2017Q4	us-gaap	Net Income Loss NetIncomeLoss	-3091000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-18912257	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10163380	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14573138	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	12519405	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	12500000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	11869823	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	11900000	USD
CY2015	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10490103	USD
CY2016	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16471603	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-10490103	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-5140000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-3524000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-6169000	USD
CY2016Q4	us-gaap	Net Income Loss NetIncomeLoss	-1639000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-16471603	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-1961000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-1799000	USD
CY2015	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-10490103	USD
CY2017	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	7772084	USD
CY2017	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2016	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2003182	USD
CY2016	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-16471603	USD
CY2017	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	7821726	USD
CY2015	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	519844	USD
CY2016	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-391556	USD
CY2017	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-53640	USD
CY2017	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2015	us-gaap	Operating Expenses OperatingExpenses	11009947	USD
CY2016	us-gaap	Operating Expenses OperatingExpenses	17233034	USD
CY2017	us-gaap	Operating Expenses OperatingExpenses	13923155	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-11009947	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-16080047	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	13889982	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	158716	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	158716	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	0	USD
CY2016	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	142000	USD
CY2017	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	142000	USD
CY2017Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	52170000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	0	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	256634	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	24272	USD
CY2015	us-gaap	Paid In Kind Interest PaidInKindInterest	293748	USD
CY2016	us-gaap	Paid In Kind Interest PaidInKindInterest	162270	USD
CY2017	us-gaap	Paid In Kind Interest PaidInKindInterest	20364	USD
CY2015	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2016	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2017	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	18888932	USD
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	19984	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	34883	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	23325	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	391253	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	703225	USD
CY2015	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	23685270	USD
CY2016	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2017	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1693498	USD
CY2015	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
CY2016	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	965000	USD
CY2017	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	4649996	USD
CY2017Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1961000	USD
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4372578	USD
CY2015	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	0	USD
CY2016	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	0	USD
CY2017	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	46861	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	130934	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	154259	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	43243	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	44612	USD
CY2015	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1811744	USD
CY2016	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	3314225	USD
CY2017	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	2374031	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6587183	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2293000	USD
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2502000	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4582000	USD
CY2016Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	773000	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10149879	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	953000	USD
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	494000	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	11111	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1959	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	62828	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	131353	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-70035083	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-58200000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-58165260	USD
CY2015	us-gaap	Revenue From Grants RevenueFromGrants	0	USD
CY2016	us-gaap	Revenue From Grants RevenueFromGrants	1152987	USD
CY2017Q1	us-gaap	Revenue From Grants RevenueFromGrants	384000	USD
CY2017Q2	us-gaap	Revenue From Grants RevenueFromGrants	158000	USD
CY2017Q3	us-gaap	Revenue From Grants RevenueFromGrants	38000	USD
CY2017Q4	us-gaap	Revenue From Grants RevenueFromGrants	45000	USD
CY2017	us-gaap	Revenue From Grants RevenueFromGrants	624569	USD
CY2015	us-gaap	Revenues Revenues	0	USD
CY2016	us-gaap	Revenues Revenues	1152987	USD
CY2017	us-gaap	Revenues Revenues	27813137	USD
CY2017	us-gaap	Sales Discounts Goods SalesDiscountsGoods	57705	USD
CY2015	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	0	USD
CY2016	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	0	USD
CY2016	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	0	USD
CY2017Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	0	USD
CY2017Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	0	USD
CY2017Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	0	USD
CY2017Q4	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1911000	USD
CY2017	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1910403	USD
CY2015	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	0	USD
CY2016	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	0	USD
CY2017Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	0	USD
CY2017	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	4	USD
CY2016	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	0	USD
CY2017	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	46861	USD
CY2017Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	0	USD
CY2017Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	0	USD
CY2017Q4	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	973000	USD
CY2017	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	973345	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	394748	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	1694891	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	1157252	USD
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1762908	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.02
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	25071	shares
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	46247	shares
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	915242	shares
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1020377	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.80
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.35
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.66
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	959188	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1849359	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2823489	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.68
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.57
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.93
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	2400000	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2823489	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	3.93
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.04
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.57
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.35
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.94
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y1M28D
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y6M4D
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y5M9D
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M15D
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P7Y3M15D
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	700000	USD
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	400000	USD
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	2900000	USD
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	997902	shares
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	2.98
CY2015	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2016	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2017	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2015	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	0	USD
CY2016	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	0	USD
CY2017	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	5858955	USD
CY2015Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	135319	USD
CY2015	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	21165589	USD
CY2016	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1899987	USD
CY2017	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1502593	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	-26330664	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	13083727	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	207002	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	27859608	USD
CY2015	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	28344157	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2015	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2016	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2017	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	344794	shares
CY2015	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2226023	shares
CY2016	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8830396	shares
CY2017	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18754799	shares
CY2015	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2226023	shares
CY2016	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8830396	shares
CY2017	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18410005	shares
CY2017	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;text-align:justify;text-indent:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company maintains a portion of its cash and cash equivalent balances in the form of a money market account with a financial institution that management believes to be creditworthy. The Company has no financial instruments with off‑balance sheet risk of loss.</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration with Customer</font><font style="font-family:Arial;font-size:10pt;font-style:italic;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company sells its prescription pharmaceutical products in the United States primarily through wholesale distributors and a specialty contracted pharmacy. Wholesale distributors account for substantially all of the Company’s net product revenues and trade receivables. In addition, the Company earns revenue from sales of its prescription pharmaceutical products directly to retail pharmacies and research and development grants. In August 2017, the Company sold all of its licensing rights for a prior product candidate, CERC-501, to a third party. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the year ended December 31, 2017, the Company’s </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> largest customers accounted for approximately </font><font style="font-family:inherit;font-size:10pt;">40%</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">25%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">22%</font><font style="font-family:inherit;font-size:10pt;">, respectively, of the Company’s total net product revenues from sale of prescription pharmaceutical products. At December 31, 2017, these top </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> customers represented, in the aggregate, approximately </font><font style="font-family:inherit;font-size:10pt;">42%</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">26%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">21%</font><font style="font-family:inherit;font-size:10pt;">, respectively, of the Company’s consolidated accounts receivable balance. </font></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company did not generate any product revenue for the year ended December 31, 2016. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Products and Sales</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> prescription pharmaceutical product lines accounted for </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> of the Company’s total product revenue, net for the year ended December 31, 2017. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company did not generate any product revenue for the year ended December 31, 2016. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration with Vendor</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s top </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> vendors accounted for approximately </font><font style="font-family:inherit;font-size:10pt;">60%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">70%</font><font style="font-family:inherit;font-size:10pt;"> of the Company’s accounts payable at December 31, 2017 and December 31, 2016, respectively.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">    </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"></font></div></div>
CY2017	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Business</font></div><div style="line-height:120%;text-align:justify;text-indent:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a biopharmaceutical company with the near-term goal of becoming a self-sustained, integrated pharmaceutical company that is focused on pediatric healthcare. We have a diverse portfolio of products and product candidates in development with a focus on patients with rare neurological and psychiatric disorders. The Company's pipeline is led by CERC-301, which Cerecor currently intends to explore as a novel treatment for orphan neurological indications. The Company is also developing </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> preclinical stage compounds, CERC-611,CERC-406 and CERC-425.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We were incorporated in 2011 and commenced operations in the second quarter of 2011.In August 2017, we sold our worldwide rights to CERC-501 to Janssen Pharmaceuticals, Inc. (“Janssen”) in exchange for initial gross proceeds of </font><font style="font-family:inherit;font-size:10pt;">$25 million</font><font style="font-family:inherit;font-size:10pt;">, of which </font><font style="font-family:inherit;font-size:10pt;">$3.75 million</font><font style="font-family:inherit;font-size:10pt;"> was deposited into a </font><font style="font-family:inherit;font-size:10pt;">twelve</font><font style="font-family:inherit;font-size:10pt;">-month escrow to secure certain indemnification obligations to Janssen, as well as a potential future </font><font style="font-family:inherit;font-size:10pt;">$20 million</font><font style="font-family:inherit;font-size:10pt;"> regulatory milestone payment. The terms of the agreement provide that Janssen will assume ongoing clinical trials and be responsible for any new development and commercialization of CERC-501. On November 17, 2017, we acquired TRx Pharmaceuticals, LLC (“TRx”) and its wholly-owned subsidiaries (see Acquisition of TRx Pharmaceuticals for a description of the transaction).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 16, 2018, we purchased and acquired all rights to Avadel Pharmaceuticals PLC’s (“Advadel's)”) marketed pediatric products (the “Acquired Products”) for the assumption of certain of Avadel's financial obligations to Deerfield CSF, LLC, which includes a </font><font style="font-family:inherit;font-size:10pt;">$15 million</font><font style="font-family:inherit;font-size:10pt;"> loan due in January 2021 and its related interest payments as well as a </font><font style="font-family:inherit;font-size:10pt;">15%</font><font style="font-family:inherit;font-size:10pt;"> annual royalty on net sales of the Acquired Products through February 2026. </font></div><div style="line-height:120%;text-align:justify;text-indent:132px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:132px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liquidity</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the year ended December 31, 2017, the Company generated net income of </font><font style="font-family:inherit;font-size:10pt;">$11.9 million</font><font style="font-family:inherit;font-size:10pt;"> and positive cash flows from operations of </font><font style="font-family:inherit;font-size:10pt;">$12.5 million</font><font style="font-family:inherit;font-size:10pt;">. Prior to the year ended December 31, 2017, the Company had incurred recurring operating losses since inception. As a result of the TRx and Avadel acquisitions, our commercial operations are expected to generate positive cash flows from product sales. </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">    </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2017, the Company had an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;">$58.2 million</font><font style="font-family:inherit;font-size:10pt;"> and a balance of </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;"> in cash and cash equivalents. The Company anticipates generating positive cash flows from our commercial operations to offset costs related to its preclinical programs, additional clinical development of its product candidates, business development and costs associated with its organizational infrastructure. We apply a disciplined decision making methodology as we evaluate the optimal allocation of our resources between investing in our current commercial product line, our development portfolio and acquisitions or in-licensing of new assets.The Company, however, may require additional financing to continue to execute its clinical development strategy. The Company plans to meet its capital requirements primarily through a combination of equity or debt financings, collaborations, or out-licensing arrangements, strategic alliances, federal and private grants, marketing, distribution or licensing arrangements and in the longer term, revenue from product sales to the extent its product candidates receive marketing approval and are commercialized. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company expects its cash on hand at December 31, 2017 and its cash flows from operations to fund future expenses through at least April 2, 2019.</font></div></div>
CY2017	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;text-align:justify;text-indent:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures. On an ongoing basis, management evaluates its estimates, including estimates related to but not limited to, revenue recognition, share-based compensation, fair value measurements (including those relating to contingent consideration), income taxes, goodwill and other intangible assets, and clinical trial accruals. The Company bases its estimates on historical experience and other market‑specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div>

Files In Submission

Name	View Source	Status
0001628280-18-003890-index-headers.html	Edgar Link	pending
0001628280-18-003890-index.html	Edgar Link	pending
0001628280-18-003890.txt	Edgar Link	pending
0001628280-18-003890-xbrl.zip	Edgar Link	pending
capture.jpg	Edgar Link	pending
capture2.jpg	Edgar Link	pending
capture3.jpg	Edgar Link	pending
cerc-20171231.xml	Edgar Link	completed
cerc-20171231.xsd	Edgar Link	pending
cerc-20171231_cal.xml	Edgar Link	unprocessable
cerc-20171231_def.xml	Edgar Link	unprocessable
cerc-20171231_lab.xml	Edgar Link	unprocessable
cerc-20171231_pre.xml	Edgar Link	unprocessable
cerc10-k20171231.htm	Edgar Link	pending
cercex-1025.htm	Edgar Link	pending
cercex-211.htm	Edgar Link	pending
cercex-231.htm	Edgar Link	pending
cercex-311.htm	Edgar Link	pending
cercex-312.htm	Edgar Link	pending
cercex-321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
offerletteragreement1_image1.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AVTX
Avalo Therapeutics, Inc. Stock $avtx

2018 Q1 Form 10-K Financial Statement

#000162828018003890 Filed on April 02, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVTX Avalo Therapeutics, Inc. Stock $avtx

2018 Q1 Form 10-K Financial Statement

#000162828018003890 Filed on April 02, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVTX
Avalo Therapeutics, Inc. Stock $avtx